Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 15

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 15
---
 4. Required Vote of Shareholders The frequency that receives the highest number of votes of the shares present in person or represented by proxy at the Meeting and entitled to vote thereon shall be approved under this Proposal 4. OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE
“FOR” “ THREE YEARS ” WITH RESPECT TO THIS PROPOSAL NO. 4. 11 PROPOSAL NO. 5 — APPROVAL OF THE SECOND AMENDED AND RESTATED 2021 EQUITY
INCENTIVE PLAN Description of Proposed Amendment On March 24, 2025, the Board of Directors unanimously approved to amend and restate (the “Plan Amendment”) the Company’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan” and as amended by the Plan Amendment, the “Second Amended and Restated 2021 Plan”), subject to stockholder approval, to increase the number of shares of common stock authorized for issuance under the current 2021 Plan by 2,500,000shares from 4,000,000 to 6,500,000shares and permit the acceleration of vesting awards upon a Change of Control (as defined below). The full text of the proposed Second Amended and Restated 2021 Plan is set out in Annex Ato this proxy statement. The text of the proposed Second Amended and Restated 2021 Plan is subject to modification to include such changes as the Board of Directors deems necessary and advisable to affect the increase in the number of shares of common stock reserved and available for issuance and permit acceleration of vesting awards upon a Change of Control. Stockholders are being asked to approve the Second Amended and Restated 2021 Plan. Vote Required and Recommendation The approval of the Second Amended and Restated 2021 Plan will be made upon the affirmative vote of the majority of shares cast on the proposal. Abstentions and broker non -voteswill have no direct effect on the outcome of this proposal. If the proposal is not approved by the stockholders, the Second Amended and Restated 2021 Plan will not be effective and the proposal will not be implemented. Reasons for the Plan Amendment Currently, awards (consisting of options to purchase shares of common stock and restricted stock) issued under the 2021 Plan totals 3,978,757 shares of common stock. On May 28, 2025, at our annual stockholders meeting, our stockholders will vote to